Department of Haematology, Royal Cornwall NHS Hospital Trust, Truro, Cornwall, UK.
Department of Haematology, Sheffield University Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
Br J Haematol. 2021 Mar;192(6):1035-1038. doi: 10.1111/bjh.16739. Epub 2020 May 23.
This is a 5-year real-world study of 65 patients treated with ibrutinib for relapsed/refractory mantle cell lymphoma across the UK and Ireland. Ibrutinib was well tolerated with no fatal adverse events. The median progression-free survival and overall survival (OS) was 12 and 18·5 months, respectively. Overall, 80% of patients discontinued treatment, predominantly for progressive disease. On discontinuation, 20% received alternative immunochemotherapy with a median OS of 24 months. Ibrutinib was used as a bridge to transplant in 8% (median OS not reached). These observations are comparable with trial outcomes with encouraging responses to immunochemotherapy at relapse.
这是一项在英国和爱尔兰进行的 65 例复发/难治性套细胞淋巴瘤患者接受伊布替尼治疗的 5 年真实世界研究。伊布替尼耐受性良好，无致命不良事件。中位无进展生存期和总生存期（OS）分别为 12 个月和 18.5 个月。总体而言，80%的患者停止治疗，主要是因为疾病进展。停药后，20%的患者接受了替代免疫化疗，中位 OS 为 24 个月。8%的患者（中位 OS 未达到）将伊布替尼作为移植的桥梁。这些观察结果与试验结果相当，复发时对免疫化疗有令人鼓舞的反应。
